DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has elected to continue diligence through the end of July with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IAFCT Injection (CFT), also known as Altropane®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease, movement disorders and Dementia with Lewy Bodies. Navidea announced in January 2012 that it had entered into an option agreement with Alseres to complete due diligence and prepare documentation necessary to execute a definitive license agreement for CFT.
